An interventional study of Timolol Maleate and No intervention in Capsule Opacification and Ocular Hypertension, sponsored by CMH Multan Institute of Medical Sciences. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by CMH Multan Institute of Medical Sciences · Not applicable, Interventional, and Prevention
This randomized controlled trial evaluated whether a single drop of 0.5% timolol maleate, administered before neodymium-doped yttrium aluminium garnet (Nd:YAG) laser posterior capsulotomy, reduced the rise in intraocular pressure compared with standard care alone. The study included adults aged 18-65 years who had developed posterior capsular opacification at least 3 months after cataract surgery and were scheduled to undergo Nd:YAG laser posterior capsulotomy. Participants were randomly assigned to receive either prophylactic topical timolol maleate or standard care without prophylactic timolol. Intraocular pressure was measured before the laser procedure and again 1 hour after the procedure by an ophthalmologist who was unaware of the assigned treatment. The study was based on the hypothesis that mean intraocular pressure 1 hour after posterior capsulotomy would be lower among participants who received prophylactic timolol maleate than among those who received standard care alone.
28 studies on the registry are indexed under Capsule Opacification; 2 are open to participants now.
This study's enrollment of 210 is above the median of 63 across 16 interventional studies indexed under Capsule Opacification.
Browse Capsule Opacification studies →CMH Multan Institute of Medical Sciences is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received one drop of 0.5% timolol maleate ophthalmic solution immediately before Nd:YAG laser posterior capsulotomy. Intraocular pressure was measured before the procedure and 1 hour after capsulotomy. Participants also received the routine postoperative treatment prescribed for both study groups.
Drug: Timolol Maleate
Participants underwent Nd:YAG laser posterior capsulotomy without receiving prophylactic timolol maleate. Intraocular pressure was measured before the procedure and 1 hour after capsulotomy. Participants received the same routine postoperative treatment as the experimental group.
Drug: No intervention
One drop of 0.5% timolol maleate ophthalmic solution was administered topically immediately before Nd:YAG laser posterior capsulotomy.
No prophylactic intraocular pressure-lowering medication was administered before Nd:YAG laser posterior capsulotomy.
Mean Intraocular Pressure 1 Hour After Nd:YAG Laser Posterior Capsulotomy
Intraocular pressure was measured in millimetres of mercury using a Canon non-contact tonometer. The mean intraocular pressure measured 1 hour after Nd:YAG laser posterior capsulotomy was compared between participants who received one drop of 0.5% topical timolol maleate before the procedure and participants who received standard care without prophylactic timolol.
Time frame: 1 hour after Nd:YAG laser posterior capsulotomy
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Timolol
CMH Multan Institute of Medical Sciences